Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from Matinas BioPharma ( (MTNB) ).
On February 5, 2025, Herbert Conrad announced his resignation from Matinas BioPharma’s Board of Directors, effective February 6, 2025, citing retirement as his reason. His departure, which includes leaving his roles on the Audit and Nominating and Corporate Governance Committees, was not due to any disagreement or strategic shift within the company.
More about Matinas BioPharma
YTD Price Performance: 1.02%
Average Trading Volume: 412,989
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $3.21M
For detailed information about MTNB stock, go to TipRanks’ Stock Analysis page.